FLT3 and acute myeloid leukemia: Gilteritinib, a pyrazine carboxamide derivative, is an orally available FDA-approved FMS-like tyrosine kinase 3 (FLT3) inhibitor that is used for treating patients with FLT3-mutated acute myeloid leukemia (AML) [17–19].